

SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe 4915 25th Ave NE Ste 204w Seattle, WA 98105-5668 Phone: (206) 588-1484

Fax: (206) 466-4696 NPI: 1306838271 Report Date: 10/16/2018 **DONOR 12374**

MALE

DOB:

Ethnicity: Northern European Sample Type: EDTA Blood Date of Collection: 10/09/2018 Date Received: 10/10/2018 Date Tested: 10/16/2018 Barcode: 11004212502545

Accession ID: CSLK4QMDELWA9YA

Indication: Egg or sperm donor

FEMALE N/A

Foresight™ Carrier Screen

NEGATIVE

ABOUT THIS TEST

The **Counsyl Foresight Carrier Screen** utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease.

RESULTS SUMMARY

Risk Details	DONOR 12374	Partner
Panel Information	Foresight Carrier Screen Universal Panel (175 conditions tested)	N/A
All conditions tested A complete list of all conditions tested can be found on page 4.	 □ NEGATIVE No disease-causing mutations were detected. 	N/A

CLINICAL NOTES NEXT STEPS

None

• If necessary, patients can discuss residual risks with their physician or a genetic counselor.



MALE

DONOR 12374

DOB:

Ethnicity: Northern European **Barcode:** 11004212502545

FEMALE N/A

Methods and Limitations

DONOR 12374 [Foresight Carrier Screen]: Sequencing with copy number analysis, spinal muscular atrophy, and analysis of homologous regions.

Sequencing with copy number analysis

High-throughput sequencing and read depth-based copy number analysis are used to analyze the listed exons, as well as selected intergenic and intronic regions, of the genes in the Conditions Tested section of the report. The region of interest (ROI) of the test comprises these regions, in addition to the 20 intronic bases flanking each exon. In a minority of cases where genomic features (e.g., long homopolymers) compromise calling fidelity, the affected intronic bases are not included in the ROI. The ROI is sequenced to high coverage and the sequences are compared to standards and references of normal variation. More than 99% of all bases in the ROI are sequenced at greater than the minimum read depth. Mutations may not be detected in areas of lower sequence coverage. Small insertions and deletions may not be as accurately determined as single nucleotide variants. Genes that have closely related pseudogenes may be addressed by a different method. *CFTR* and *DMD* testing includes analysis for both large (exon-level) deletions and duplications with an average sensitivity of 99%, while other genes are only analyzed for large deletions with a sensitivity of >75%. However, the sensitivity may be higher for selected founder deletions. If *GJB2* is tested, two large upstream deletions which overlap *GJB6* and affect the expression of *GJB2*, del(*GJB6*-D13S1830) and del(*GJB6*-D13S1854), are also analyzed. Mosaicism or somatic variants present at low levels may not be detected. If detected, these may not be reported.

Detection rates are determined by using literature to estimate the fraction of disease alleles, weighted by frequency, that the methodology is unable to detect. Detection rates only account for analytical sensitivity and certain variants that have been previously described in the literature may not be reported if there is insufficient evidence for pathogenicity. Detection rates do not account for the disease-specific rates of de novo mutations.

All variants that are a recognized cause of the disease will be reported. In addition, variants that have not previously been established as a recognized cause of disease may be identified. In these cases, only variants classified as "likely" pathogenic are reported. Likely pathogenic variants are described elsewhere in the report as "likely to have a negative impact on gene function". Likely pathogenic variants are evaluated and classified by assessing the nature of the variant and reviewing reports of allele frequencies in cases and controls, functional studies, variant annotation and effect prediction, and segregation studies. Exon level duplications are assumed to be in tandem and are classified according to their predicted effect on the reading frame. Benign variants, variants of uncertain significance, and variants not directly associated with the intended disease phenotype are not reported. Curation summaries of reported variants are available upon request.

Spinal muscular atrophy

Targeted copy number analysis is used to determine the copy number of exon 7 of the *SMN1* gene relative to other genes. Other mutations may interfere with this analysis. Some individuals with two copies of *SMN1* are carriers with two *SMN1* genes on one chromosome and a *SMN1* deletion on the other chromosome. This is more likely in individuals who have 2 copies of the *SMN1* gene and are positive for the g.27134T>G SNP, which affects the reported residual risk; Ashkenazi Jewish or Asian patients with this genotype have a high post-test likelihood of being carriers for SMA and are reported as carriers. The g.27134T>G SNP is only reported in individuals who have 2 copies of *SMN1*.

Analysis of homologous regions

A combination of high-throughput sequencing, read depth-based copy number analysis, and targeted genotyping is used to determine the number of functional gene copies and/or the presence of selected loss of function mutations in certain genes that have homology to other regions. The precise breakpoints of large deletions in these genes cannot be determined, but are estimated from copy number analysis. High numbers of pseudogene copies may interfere with this analysis.

If *CYP21A2* is tested, patients who have one or more additional copies of the *CYP21A2* gene and a loss of function mutation may not actually be a carrier of 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH). Because the true incidence of non-classic CAH is unknown, the residual carrier and reproductive risk numbers on the report are only based on published incidences for classic CAH. However, the published prevalence of non-classic CAH is highest in individuals of Ashkenazi Jewish, Hispanic, Italian, and Yugoslav descent. Therefore, the residual and reproductive risks are likely an underestimate of overall chances for 21-hydroxylase-deficient CAH, especially in the aforementioned populations, as they do not account for non-classic CAH. If *HBA11HBA2* are tested, some individuals with four alpha globin genes may be carriers, with three genes on one chromosome and a deletion on the other chromosome. This and similar, but rare, carrier states, where complementary changes exist in both the gene and a pseudogene, may not be detected by the assay.



RESULTS RECIPIENT

SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe

NPI: 1306838271

Report Date: 10/16/2018

MALE
DONOR 12374
DOB

Ethnicity: Northern European **Barcode:** 11004212502545

FEMALE N/A

Limitations

In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, bone marrow transplantation, blood transfusions and technical errors. This test is designed to detect and report germline alterations. While somatic variants present at low levels may be detected, these may not be reported. If more than one variant is detected in a gene, additional studies may be necessary to determine if those variants lie on the same chromosome or different chromosomes. The test does not fully address all inherited forms of intellectual disability, birth defects and genetic disease. A family history of any of these conditions may warrant additional evaluation. Furthermore, not all mutations will be identified in the genes analyzed and additional testing may be beneficial for some patients. For example, individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies, which can be identified by CBC and hemoglobin electrophoresis or HPLC (ACOG Practice Bulletin No. 78. Obstet. Gynecol. 2007;109:229-37).

This test was developed and its performance characteristics determined by Myriad Women's Health, Inc. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA does not require this test to go through premarket review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These results are adjunctive to the ordering physician's evaluation. CLIA Number: #05D1102604.

LABORATORY DIRECTOR

Hyunseok Kang

H. Peter Kang, MD, MS, FCAP

Report content approved by Saurav Guha, PhD, FACMG on Oct 16, 2018



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271 Report Date: 10/16/2018 MALE DONOR 12374

DONOR 12374 DOB

Ethnicity: Northern European Barcode: 11004212502545

FEMALE N/A

Conditions Tested

11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia - **Gene**: CYP11B1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000497:1-9. **Detection Rate**: Northern European 94%.

21-hydroxylase-deficient Congenital Adrenal Hyperplasia - Gene: CYP21A2. Autosomal Recessive. Analysis of homologous regions. Variants (13): CYP21A2 deletion, CYP21A2 duplication, CYP21A2 triplication, G111Vfs*21, I173N, L308Ffs*6, P31L, Q319*, Q319*+CYP21A2dup, R357W, V281L, [I237N;V238E;M240K], c.293-13C>G. Detection Rate: Northern European 96%.

6-pyruvoyl-tetrahydropterin Synthase Deficiency - **Gene**: PTS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000317:1-6. **Detection Rate**: Northern European >99%.

ABCC8-related Hyperinsulinism - **Gene:** ABCC8. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000352:1-39. **Detection Rate:** Northern Furnnean >99%

Adenosine Deaminase Deficiency - Gene: ADA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000022:1-12. Detection Rate: Northern European >99%.

Alpha Thalassemia - **Genes**: HBA1, HBA2. Autosomal Recessive. Analysis of homologous regions. **Variants** (13): -(alpha)20.5, --BRIT, --MEDI, --MEDI, --SEA, -- THAI or --FIL, -alpha3.7, -alpha4.2, HBA1+HBA2 deletion, Hb Constant Spring, anti3.7, anti4.2, del HS-40. **Detection Rate**: Unknown due to rarity of disease.

Alpha-mannosidosis - **Gene**: MAN2B1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000528:1-23. **Detection Rate**: Northern European >99%.

Alpha-sarcoglycanopathy - **Gene:** SGCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000023:1-9. **Detection Rate:** Northern European >99%.

Alstrom Syndrome - **Gene**: ALMS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_015120:1-23. **Detection Rate**: Northern European >99%.

AMT-related Glycine Encephalopathy - **Gene**: AMT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000481:1-9. **Detection Rate**: Northern European >99%.

Andermann Syndrome - **Gene:** SLC12A6. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_133647:1-25. **Detection Rate:** Northern European >99%.

Argininemia - Gene: ARG1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001244438:1-8. Detection Rate: Northern European 97%. Argininosuccinic Aciduria - Gene: ASL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001024943:1-16. Detection Rate: Northern European >99%

ARSACS - **Gene**: SACS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM 014363:2-10. **Detection Rate**: Northern European 99%.

Aspartylglycosaminuria - **Gene:** AGA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000027:1-9. **Detection Rate:** Northern European >99%

Ataxia with Vitamin E Deficiency - Gene: TTPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000370:1-5. **Detection Rate:** Northern European >99%.

Ataxia-telangiectasia - Gene: ATM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000051:2-63. Detection Rate: Northern European 98%

ATP7A-related Disorders - **Gene**: ATP7A. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM_000052:2-23. **Detection Rate**: Northern European 96%.

Autosomal Recessive Osteopetrosis Type 1 - Gene: TCIRG1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_006019:2-20. Detection Rate: Northern European >99%

Bardet-Biedl Syndrome, BBS1-related - **Gene**: BBS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_024649:1-17. **Detection Rate**: Northern European >99%.

Bardet-Biedl Syndrome, BBS10-related - Gene: BBS10. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_024685:1-2. **Detection Rate**: Northern European >99%.

Bardet-Biedl Syndrome, BBS12-related - **Gene:** BBS12. Autosomal Recessive. Sequencing with copy number analysis. **Exon:** NM_152618:2. **Detection Rate:** Northern European >99%.

Bardet-Biedl Syndrome, BBS2-related - Gene: BBS2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_031885:1-17. **Detection Rate:** Northern European >99%.

Beta-sarcoglycanopathy - **Gene:** SGCB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000232:1-6. **Detection Rate:** Northern European >99%.

Biotinidase Deficiency - **Gene**: BTD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000060:1-4. **Detection Rate**: Northern European >99%.

Bloom Syndrome - **Gene:** BLM. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000057:2-22. **Detection Rate**: Northern European

Calpainopathy - Gene: CAPN3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000070:1-24. Detection Rate: Northern European >99%. Canavan Disease - Gene: ASPA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000049:1-6. Detection Rate: Northern European 98%. Carbamoylphosphate Synthetase I Deficiency - Gene: CPS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001875:1-38. Detection Rate: Northern European >99%.

Carnitine Palmitoyltransferase IA Deficiency - **Gene:** CPT1A. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001876:2-19. **Detection Rate:** Northern European >99%.

Carnitine Palmitoyltransferase II Deficiency - Gene: CPT2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000098:1-5. Detection Rate: Northern European >99%.

Cartilage-hair Hypoplasia - Gene: RMRP. Autosomal Recessive. Sequencing with copy number analysis. Exon: NR_003051:1. Detection Rate: Northern European

Cerebrotendinous Xanthomatosis - **Gene**: CYP27A1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000784:1-9. **Detection Rate**: Northern European >99%.

Citrullinemia Type 1 - Gene: ASS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000050:3-16. Detection Rate: Northern European

CLN3-related Neuronal Ceroid Lipofuscinosis - Gene: CLN3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001042432:2-16. Detection Rate: Northern European >99%.

CLN5-related Neuronal Ceroid Lipofuscinosis - **Gene**: CLN5. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_006493:1-4. **Detection Rate**: Northern European >99%.

CLN6-related Neuronal Ceroid Lipofuscinosis - Gene: CLN6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_017882:1-7. Detection Rate: Northern European >99%.

Cohen Syndrome - **Gene**: VPS13B. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_017890:2-62. **Detection Rate**: Northern European 97%.

COL4A3-related Alport Syndrome - **Gene**: COL4A3. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000091:1-52. **Detection Rate**: Northern European 97%.

COL4A4-related Alport Syndrome - Gene: COL4A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000092:2-48. **Detection Rate:** Northern European 98%.

Congenital Disorder of Glycosylation Type Ia - Gene: PMM2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000303:1-8. Detection Rate: Northern European >99%.

Congenital Disorder of Glycosylation Type Ib - Gene: MPI. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_002435:1-8. Detection Rate: Northern European >99%.

Congenital Disorder of Glycosylation Type Ic - Gene: ALG6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_013339:2-15. Detection Rate: Northern European >99%.



SEATTLE SPERM BANK
Attn: Dr. Jeffrey Olliffe
NPI: 1306838271

Report Date: 10/16/2018

MALE

DOB₂

DONOR 12374

Ethnicity: Northern European Barcode: 11004212502545

FEMALE N/A

GLDC-related Glycine Encephalopathy - **Gene:** GLDC. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000170:1-25. **Detection Rate:** Northern European 94%.

Glutaric Acidemia Type 1 - **Gene**: GCDH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000159:2-12. **Detection Rate**: Northern European >99%.

Glycogen Storage Disease Type Ia - **Gene**: G6PC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000151:1-5. **Detection Rate**: Northern European >99%.

Glycogen Storage Disease Type Ib - **Gene:** SLC37A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001164277:3-11. **Detection Rate:** Northern European >99%.

Glycogen Storage Disease Type III - Gene: AGL. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000642:2-34. **Detection Rate**: Northern European >99%.

GNPTAB-related Disorders - Gene: GNPTAB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_024312:1-21. **Detection Rate**: Northern European >99%.

GRACILE Syndrome - **Gene:** BCS1L. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_004328:3-9. **Detection Rate:** Northern European >99%.

HADHA-related Disorders - **Gene**: HADHA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000182:1-20. **Detection Rate**: Northern European >99%.

Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease) - Gene: HBB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000518:1-3. Detection Rate: Northern European >99%.

Hereditary Fructose Intolerance - **Gene**: ALDOB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000035:2-9. **Detection Rate**: Northern European >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMA3-related - Gene: LAMA3. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000227:1-38. **Detection Rate**: Northern European >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMB3-related - Gene: LAMB3. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000228:2-23. **Detection Rate**: Northern European >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMC2-related - **Gene**: LAMC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_005562:1-23. **Detection Rate**: Northern European >99%.

Hexosaminidase A Deficiency (Including Tay-Sachs Disease) - **Gene:** HEXA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000520:1-14. **Detection Rate:** Northern European >99%.

HMG-CoA Lyase Deficiency - Gene: HMGCL. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000191:1-9. **Detection Rate**: Northern European 98%.

Holocarboxylase Synthetase Deficiency - Gene: HLCS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000411:4-12. **Detection Rate**: Northern European >99%.

Homocystinuria Caused by Cystathionine Beta-synthase Deficiency - Gene: CBS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000071:3-17. Detection Rate: Northern European >99%.

Hydrolethalus Syndrome - **Gene**: HYLS1. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM_001134793:3. **Detection Rate**: Northern European >99%.

Hypophosphatasia, Autosomal Recessive - **Gene**: ALPL. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000478:2-12. **Detection Rate**: Northern European >99%.

Inclusion Body Myopathy 2 - **Gene:** GNE. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001128227:1-12. **Detection Rate:** Northern European >99%.

Isovaleric Acidemia - **Gene**: IVD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_002225:1-12. **Detection Rate**: Northern European >99%.

Joubert Syndrome 2 - Gene: TMEM216. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001173990:1-5. **Detection Rate**: Northern European \$490%

KCNJ11-related Familial Hyperinsulinism - **Gene**: KCNJ11. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM_000525:1. **Detection Rate**: Northern European >99%.

Congenital Finnish Nephrosis - **Gene:** NPHS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_004646:1-29. **Detection Rate:** Northern European >99%.

Costeff Optic Atrophy Syndrome - Gene: OPA3. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_025136:1-2. **Detection Rate:** Northern European >99%.

Cystic Fibrosis - Gene: CFTR. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000492:1-27. IVS8-5T allele analysis is only reported in the presence of the R117H mutation. Detection Rate: Northern European >99%. Cystinosis - Gene: CTNS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_004937:3-12. Detection Rate: Northern European >99%. D-bifunctional Protein Deficiency - Gene: HSD17B4. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000414:1-24. Detection Rate: Northern European 98%.

Delta-sarcoglycanopathy - **Gene**: SGCD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000337:2-9. **Detection Rate**: Northern European 99%.

Dysferlinopathy - **Gene**: DYSF. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001130987:1-56. **Detection Rate**: Northern European 98%. **Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy)** - **Gene**: DMD. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM 004006:1-79. **Detection Rate**: Northern European >99%.

ERCC6-related Disorders - Gene: ERCC6. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000124:2-21. **Detection Rate:** Northern European 99%.

ERCC8-related Disorders - Gene: ERCC8. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000082:1-12. **Detection Rate:** Northern European 95%.

EVC-related Ellis-van Creveld Syndrome - **Gene**: EVC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_153717:1-21. **Detection Rate**: Northern European 96%.

EVC2-related Ellis-van Creveld Syndrome - Gene: EVC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_147127:1-22. **Detection Rate**: Northern European >99%.

Fabry Disease - Gene: GLA. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000169:1-7. Detection Rate: Northern European 98%.

Familial Dysautonomia - Gene: IKBKAP. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_003640:2-37. Detection Rate: Northern European >99%.

Familial Mediterranean Fever - Gene: MEFV. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000243:1-10. Detection Rate: Northern European >99%.

Fanconi Anemia Complementation Group A - **Gene**: FANCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000135:1-43. **Detection Rate**: Northern European 92%.

Fanconi Anemia Type C - **Gene**: FANCC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000136:2-15. **Detection Rate**: Northern European >99%.

FKRP-related Disorders - **Gene**: FKRP. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM_024301:4. **Detection Rate**: Northern European >99%. **FKTN-related Disorders** - **Gene**: FKTN. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_001079802:3-11. **Detection Rate**: Northern European >99%.

Galactokinase Deficiency - **Gene:** GALK1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000154:1-8. **Detection Rate:** Northern European >99%. **Galactosemia** - **Gene:** GALT. Autosomal Recessive. Sequencing with copy number

analysis. Exons: NM_000155:1-11. Detection Rate: Northern European >99%. Gamma-sarcoglycanopathy - Gene: SGCG. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000231:2-8. Detection Rate: Northern European 88%.

Gaucher Disease - **Gene**: GBA. Autosomal Recessive. Analysis of homologous regions. **Variants (10)**: D409V, D448H, IVS2+1G>A, L444P, N370S, R463C, R463H, R496H, V394L, p.L29Afs*18. **Detection Rate**: Northern European 60%.

GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness - Gene: GJB2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_004004:1-2. **Detection Rate:** Northern European >99%.

GLB1-related Disorders - Gene: GLB1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000404:1-16. **Detection Rate**: Northern European >99%.



NPI: 1306838271

SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe

Report Date: 10/16/2018

MALE

DOB₂

DONOR 12374

Ethnicity: Northern European **Barcode:** 11004212502545

FEMALE N/A

Krabbe Disease - Gene: GALC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000153:1-17. Detection Rate: Northern European >99%.

LAMA2-related Muscular Dystrophy - **Gene**: LAMA2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000426:1-65. **Detection Rate**: Northern European >99%.

Leigh Syndrome, French-Canadian Type - **Gene**: LRPPRC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_133259:1-38. **Detection Rate**: Northern European >99%.

Lipoamide Dehydrogenase Deficiency - **Gene**: DLD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000108:1-14. **Detection Rate**: Northern European >99%.

Lipoid Congenital Adrenal Hyperplasia - Gene: STAR. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000349:1-7. **Detection Rate**: Northern European >99%.

Lysosomal Acid Lipase Deficiency - Gene: LIPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000235:2-10. **Detection Rate:** Northern European >99%.

Maple Syrup Urine Disease Type 1B - **Gene:** BCKDHB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_183050:1-10. **Detection Rate:** Northern European >99%.

Maple Syrup Urine Disease Type Ia - **Gene:** BCKDHA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000709:1-9. **Detection Rate:** Northern European >99%.

Maple Syrup Urine Disease Type II - Gene: DBT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001918:1-11. Detection Rate: Northern European 96%.

Medium Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000016:1-12. Detection Rate: Northern European >99%.

Megalencephalic Leukoencephalopathy with Subcortical Cysts - **Gene**: MLC1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_015166:2-12. **Detection Rate**: Northern European >99%.

Metachromatic Leukodystrophy - **Gene**: ARSA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000487:1-8. **Detection Rate**: Northern European >99%.

Methylmalonic Acidemia, cblA Type - **Gene**: MMAA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_172250:2-7. **Detection Rate:** Northern European >99%.

Methylmalonic Acidemia, cblB Type - **Gene**: MMAB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_052845:1-9. **Detection Rate**: Northern European >99%.

Methylmalonic Aciduria and Homocystinuria, cblC Type - **Gene**: MMACHC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_015506:1-4. **Detection Rate**: Northern European >99%.

MKS1-related Disorders - Gene: MKS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_017777:1-18. Detection Rate: Northern European >99%

Mucolipidosis III Gamma - Gene: GNPTG. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_032520:1-11. **Detection Rate:** Northern European >99%.

Mucolipidosis IV - **Gene:** MCOLN1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_020533:1-14. **Detection Rate:** Northern European >99%.

Mucopolysaccharidosis Type I - **Gene**: IDUA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000203:1-14. **Detection Rate**: Northern European >99%.

Mucopolysaccharidosis Type II - **Gene**: IDS. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM_000202:1-9. **Detection Rate**: Northern European 88%.

Mucopolysaccharidosis Type IIIA - **Gene**: SGSH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000199:1-8. **Detection Rate**: Northern European >99%.

Mucopolysaccharidosis Type IIIB - Gene: NAGLU. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000263:1-6. **Detection Rate**: Northern European >99%.

Mucopolysaccharidosis Type IIIC - Gene: HGSNAT. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_152419:1-18. **Detection Rate:** Northern European >99%.

Muscle-eye-brain Disease - **Gene:** POMGNT1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_017739:2-22. **Detection Rate:** Northern European 96%.

MUT-related Methylmalonic Acidemia - **Gene**: MUT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000255:2-13. **Detection Rate**: Northern European >99%.

MYO7A-related Disorders - Gene: MYO7A. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000260:2-49. Detection Rate: Northern European >99%.

NEB-related Nemaline Myopathy - **Gene:** NEB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_001271208:3-80,117-183. **Detection Rate:** Northern European 92%.

Nephrotic Syndrome, NPHS2-related - **Gene:** NPHS2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_014625:1-8. **Detection Rate:** Northern European >99%.

Niemann-Pick Disease Type C - Gene: NPC1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000271:1-25. **Detection Rate**: Northern European >99%.

Niemann-Pick Disease Type C2 - **Gene:** NPC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_006432:1-5. **Detection Rate:** Northern European >99%.

Niemann-Pick Disease, SMPD1-associated - **Gene:** SMPD1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000543:1-6. **Detection Rate:** Northern European >99%.

Nijmegen Breakage Syndrome - **Gene:** NBN. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_002485:1-16. **Detection Rate:** Northern European >99%.

Northern Epilepsy - **Gene:** CLN8. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_018941:2-3. **Detection Rate:** Northern European >99%

Ornithine Transcarbamylase Deficiency - Gene: OTC. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM_000531:1-10. **Detection Rate**: Northern European 97%.

PCCA-related Propionic Acidemia - **Gene**: PCCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000282:1-24. **Detection Rate**: Northern European 95%.

PCCB-related Propionic Acidemia - Gene: PCCB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001178014:1-16. Detection Rate: Northern European >99%.

PCDH15-related Disorders - **Gene:** PCDH15. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_033056:2-33. **Detection Rate:** Northern European 93%.

Pendred Syndrome - Gene: SLC26A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000441:2-21. **Detection Rate:** Northern European

Peroxisome Biogenesis Disorder Type 3 - **Gene**: PEX12. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000286:1-3. **Detection Rate:** Northern European >99%.

Peroxisome Biogenesis Disorder Type 4 - Gene: PEX6. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000287:1-17. **Detection Rate**: Northern European 97%.

Peroxisome Biogenesis Disorder Type 5 - **Gene**: PEX2. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM_000318:4. **Detection Rate**: Northern European >99%.

Peroxisome Biogenesis Disorder Type 6 - **Gene**: PEX10. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_153818:1-6. **Detection Rate**: Northern European >99%.

PEX1-related Zellweger Syndrome Spectrum - **Gene**: PEX1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000466:1-24. **Detection Rate**: Northern European >99%.

Phenylalanine Hydroxylase Deficiency - **Gene:** PAH. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000277:1-13. **Detection Rate:** Northern European >99%.

PKHD1-related Autosomal Recessive Polycystic Kidney Disease - Gene: PKHD1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_138694:2-67. Detection Rate: Northern European >99%.

Polyglandular Autoimmune Syndrome Type 1 - **Gene**: AIRE. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM_000383:1-14. **Detection Rate**: Northern European >99%.



SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe

NPI: 1306838271 Report Date: 10/16/2018

MALE

DOB₂

DONOR 12374

Ethnicity: Northern European Barcode: 11004212502545

FEMALE N/A

Pompe Disease - Gene: GAA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000152:2-20. Detection Rate: Northern European 98%. PPT1-related Neuronal Ceroid Lipofuscinosis - Gene: PPT1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000310:1-9. Detection Rate: Northern European >99%.

Primary Carnitine Deficiency - Gene: SLC22A5. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_003060:1-10. Detection Rate: Northern European >99%

Primary Hyperoxaluria Type 1 - Gene: AGXT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000030:1-11. Detection Rate: Northern European >99%.

Primary Hyperoxaluria Type 2 - Gene: GRHPR. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_012203:1-9. Detection Rate: Northern

Primary Hyperoxaluria Type 3 - Gene: HOGA1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_138413:1-7. Detection Rate: Northern European >99%

PROP1-related Combined Pituitary Hormone Deficiency - Gene: PROP1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM 006261:1-3. Detection Rate: Northern European >99%.

Pycnodysostosis - Gene: CTSK. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM 000396:2-8. Detection Rate: Northern European >99%.

Pyruvate Carboxylase Deficiency - Gene: PC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_022172:2-21. Detection Rate: Northern European >99%

Rhizomelic Chondrodysplasia Punctata Type 1 - Gene: PEX7. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000288:1-10. Detection Rate: Northern European >99%.

RTEL1-related Disorders - Gene: RTEL1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_032957:2-35. Detection Rate: Northern European >99%.

Salla Disease - Gene: SLC17A5. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_012434:1-11. Detection Rate: Northern European 98%. Sandhoff Disease - Gene: HEXB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000521:1-14. Detection Rate: Northern European

Segawa Syndrome - Gene: TH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000360:1-13. Detection Rate: Northern European >99%. Short Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000017:1-10. Detection Rate: Northern European >99%.

Sjogren-Larsson Syndrome - Gene: ALDH3A2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000382:1-10. Detection Rate: Northern European 97%.

Smith-Lemli-Opitz Syndrome - Gene: DHCR7. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001360:3-9. Detection Rate: Northern European >99%

Spastic Paraplegia Type 15 - Gene: ZFYVE26. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_015346:2-42. Detection Rate: Northern European >99%.

Spinal Muscular Atrophy - Gene: SMN1. Autosomal Recessive. Spinal muscular atrophy. Variant (1): SMN1 copy number. Detection Rate: Northern European 95%. Spondylothoracic Dysostosis - Gene: MESP2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_001039958:1-2. Detection Rate: Northern European >99%.

Sulfate Transporter-related Osteochondrodysplasia - Gene: SLC26A2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000112:2-3. Detection Rate: Northern European >99%

TGM1-related Autosomal Recessive Congenital Ichthyosis - Gene: TGM1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000359:2-15. Detection Rate: Northern European >99%.

TPP1-related Neuronal Ceroid Lipofuscinosis - Gene: TPP1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM_000391:1-13. **Detection Rate:** Northern European >99%

Tyrosinemia Type I - Gene: FAH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000137:1-14. Detection Rate: Northern European

Tyrosinemia Type II - Gene: TAT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000353:2-12. Detection Rate: Northern European >99%

USH1C-related Disorders - Gene: USH1C. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_153676:1-27. Detection Rate: Northern European >99%

USH2A-related Disorders - Gene: USH2A. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_206933:2-72. Detection Rate: Northern European 94%.

Usher Syndrome Type 3 - Gene: CLRN1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_174878:1-3. Detection Rate: Northern European

Very Long Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADVL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000018:1-20. **Detection Rate:** Northern European >99%.

Wilson Disease - Gene: ATP7B. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000053:1-21. Detection Rate: Northern European >99%. X-linked Adrenoleukodystrophy - Gene: ABCD1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000033:1-6. Detection Rate: Northern European 77%.

X-linked Alport Syndrome - Gene: COL4A5. X-linked Recessive. Sequencing with copy number analysis. Exons: NM 000495:1-51. Detection Rate: Northern European 95%

X-linked Congenital Adrenal Hypoplasia - Gene: NROB1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000475:1-2. Detection Rate: Northern European 99%.

X-linked Juvenile Retinoschisis - Gene: RS1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000330:1-6. Detection Rate: Northern European

X-linked Myotubular Myopathy - Gene: MTM1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000252:2-15. Detection Rate: Northern European 98%.

X-linked Severe Combined Immunodeficiency - Gene: IL2RG. X-linked Recessive. Sequencing with copy number analysis. Exons: NM_000206:1-8. Detection Rate: Northern European >99%.

Xeroderma Pigmentosum Group A - Gene: XPA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_000380:1-6. Detection Rate: Northern European >99%.

Xeroderma Pigmentosum Group C - Gene: XPC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM_004628:1-16. Detection Rate: Northern



MALE

DONOR 12374

DOB:

Ethnicity: Northern European **Barcode:** 11004212502545

FEMALE N/A

Risk Calculations

Below are the risk calculations for all conditions tested. Since negative results do not completely rule out the possibility of being a carrier, the **residual risk** represents the patient's post-test likelihood of being a carrier and the **reproductive risk** represents the likelihood the patient's future children could inherit each disease. These risks are inherent to all carrier screening tests, may vary by ethnicity, are predicated on a negative family history and are present even after a negative test result. Inaccurate reporting of ethnicity may cause errors in risk calculation. The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Disease	DONOR 12374 Residual Risk	Reproductive Risk
11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 3,800	< 1 in 1,000,000
21-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 1,400	1 in 310,000
-pyruvoyl-tetrahydropterin Synthase Deficiency	< 1 in 50,000	< 1 in 1,000,000
BCC8-related Hyperinsulinism	1 in 11,000	< 1 in 1,000,000
denosine Deaminase Deficiency	1 in 22,000	< 1 in 1,000,000
Alpha Thalassemia	Alpha globin status: aa/aa.	Not calculated
Alpha-mannosidosis	1 in 35,000	< 1 in 1,000,000
lpha-sarcoglycanopathy	1 in 45,000	< 1 in 1,000,000
llstrom Syndrome	< 1 in 50,000	< 1 in 1,000,000
MT-related Glycine Encephalopathy	1 in 22,000	< 1 in 1,000,000
Andermann Syndrome	< 1 in 50,000	< 1 in 1,000,000
Argininemia	< 1 in 17,000	< 1 in 1,000,000
rgininosuccinic Aciduria	1 in 13,000	< 1 in 1,000,000
IRSACS	< 1 in 44,000	< 1 in 1,000,000
Aspartylglycosaminuria	< 1 in 50,000	< 1 in 1,000,000
taxia with Vitamin E Deficiency	< 1 in 50,000	< 1 in 1,000,000
taxia-telangiectasia	1 in 8,200	< 1 in 1,000,000
TP7A-related Disorders	< 1 in 1,000,000	1 in 600,000
autosomal Recessive Osteopetrosis Type 1	1 in 35,000	< 1 in 1,000,000
ardet-Biedl Syndrome, BBS1-related	1 in 16,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS10-related	1 in 16,000	< 1 in 1,000,000
ardet-Biedl Syndrome, BBS12-related	< 1 in 50,000	< 1 in 1,000,000
ardet-Biedl Syndrome, BBS2-related	< 1 in 50,000	< 1 in 1,000,000
eta-sarcoglycanopathy	< 1 in 50,000	< 1 in 1,000,000
iotinidase Deficiency	1 in 13,000	1 in 650,000
loom Syndrome	< 1 in 50,000	< 1 in 1,000,000
alpainopathy	1 in 13,000	< 1 in 1,000,000
	•	
anavan Disease	<1 in 31,000	< 1 in 1,000,000
arbamoylphosphate Synthetase I Deficiency	< 1 in 57,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase IA Deficiency	< 1 in 50,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase II Deficiency	< 1 in 50,000	< 1 in 1,000,000
artilage-hair Hypoplasia	< 1 in 50,000	< 1 in 1,000,000
erebrotendinous Xanthomatosis	1 in 11,000	< 1 in 1,000,000
Citrullinemia Type 1	1 in 12,000	< 1 in 1,000,000
LN3-related Neuronal Ceroid Lipofuscinosis	1 in 22,000	< 1 in 1,000,000
LN5-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
LN6-related Neuronal Ceroid Lipofuscinosis	1 in 43,000	< 1 in 1,000,000
ohen Syndrome	< 1 in 15,000	< 1 in 1,000,000
OL4A3-related Alport Syndrome	1 in 6,200	< 1 in 1,000,000
OL4A4-related Alport Syndrome	1 in 12,000	< 1 in 1,000,000
ongenital Disorder of Glycosylation Type Ia	1 in 16,000	< 1 in 1,000,000
ongenital Disorder of Glycosylation Type Ib	< 1 in 50,000	< 1 in 1,000,000
ongenital Disorder of Glycosylation Type Ic	< 1 in 50,000	< 1 in 1,000,000
ongenital Finnish Nephrosis	< 1 in 50,000	< 1 in 1,000,000
osteff Optic Atrophy Syndrome	< 1 in 50,000	< 1 in 1,000,000
ystic Fibrosis	1 in 2,700	1 in 290,000
ystinosis	1 in 22,000	< 1 in 1,000,000
D-bifunctional Protein Deficiency	1 in 9,000	< 1 in 1,000,000
Delta-sarcoglycanopathy	< 1 in 40,000	< 1 in 1,000,000
Dysferlinopathy	1 in 11,000	< 1 in 1,000,000



MALE

DONOR 12374

DOB

Ethnicity: Northern European Barcode: 11004212502545

FEMALE N/A

Destrophinopathy (Including Duchenne/Becker Muscular Dystrophy)	Disease	DONOR 12374 Residual Risk	Reproductive Risk
ERCCE-elated Disorders	Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy)		
EVC-related Ellis-wan Crevel Syndrome		1 in 26,000	< 1 in 1,000,000
EVC2-related Ellis-van Creveld Syndrome	ERCC8-related Disorders	< 1 in 9,900	< 1 in 1,000,000
Fabry Disease	EVC-related Ellis-van Creveld Syndrome	1 in 7,500	< 1 in 1,000,000
Familial Modifectranean Fever	EVC2-related Ellis-van Creveld Syndrome	< 1 in 50,000	< 1 in 1,000,000
Familial Mediterranean Fever	Fabry Disease	< 1 in 1,000,000	1 in 80,000
Fanconi Amenia Complementation Group A	Familial Dysautonomia	< 1 in 50,000	< 1 in 1,000,000
Fancon Anemia Type C		< 1 in 50,000	< 1 in 1,000,000
FKRP-related Disorders	Fanconi Anemia Complementation Group A		
FKTN-related Disorders	• • • • • • • • • • • • • • • • • • • •	•	· · ·
Salactoximase Deficiency			
Salactosemia			
Gamma-sarcoglycanopathy	•		
Gaucher Disease 1 in 280 1 in 120,000 1 in			
GIBZ-related DFNB1 Nonsyndromic Hearing Loss and Deafness 1 in 3,200			
CLD-related Disorders			
CID-Crelated Glycine Encephalopathy			
Glutaric Acidemia Type 1		•	
Glycogen Storage Disease Type 1			
Glycogen Storage Disease Type III			
Givcogen Storage Disease Type III			
CAPTAB-related Disorders			
CRACILE Syndrome		•	
HADHA-related Disorders 1 in 15,000 1 in 190,000 1 in 99,000 1 in 10,000,000 1 i			
Sickle Cell Disease) 1 in 5,000 1 in 9,000 Herreditary Fructose Intolerance 1 in 8,000 <1 in 1,000,000			
Hereditary Fructose Intolerance	- · · · · · · · · · · · · · · · · · · ·	1 in 5,000	1 in 990,000
Herlitz Junctional Epidermolysis Bullosa, LAMA3-related	·	1 in 8 000	< 1 in 1 000 000
Herlitz Junctional Epidermolysis Bullosa, LAMB3-related			
Herlitz Junctional Epidermolysis Bullosa, LAMC2-related			
Hexosaminidase A Deficiency (Including Tay-Sachs Disease)			
HMG-CoA Lyase Deficiency			
Homocystinuria Caused by Cystathionine Beta-synthase Deficiency		< 1 in 33,000	< 1 in 1,000,000
Hydrolethalus Syndrome	Holocarboxylase Synthetase Deficiency	1 in 15,000	< 1 in 1,000,000
Hypophosphatasia, Autosomal Recessive	Homocystinuria Caused by Cystathionine Beta-synthase Deficiency	1 in 25,000	< 1 in 1,000,000
Inclusion Body Myopathy 2	Hydrolethalus Syndrome	< 1 in 50,000	< 1 in 1,000,000
Sovaleric Acidemia		1 in 16,000	< 1 in 1,000,000
Joubert Syndrome 2		< 1 in 50,000	< 1 in 1,000,000
KCNJ11-related Familial Hyperinsulinism <1 in 50,000 <1 in 1,000,000 Krabbe Disease 1 in 15,000 <1 in 1,000,000 LAMA2-related Muscular Dystrophy 1 in 34,000 <1 in 1,000,000 Leigh Syndrome, French-Canadian Type <1 in 50,000 <1 in 1,000,000 Lipoamide Dehydrogenase Deficiency <1 in 50,000 <1 in 1,000,000 Lipoid Congenital Adrenal Hyperplasia <1 in 50,000 <1 in 1,000,000 Lysosomal Acid Lipase Deficiency 1 in 18,000 <1 in 1,000,000 Maple Syrup Urine Disease Type 1B 1 in 25,000 <1 in 1,000,000 Maple Syrup Urine Disease Type Ia 1 in 142,000 <1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Metachromatic Leukoencephalopathy with Subcortical Cysts 1 in 50,000 <1 in 1,000,000 Metachromatic Leukoencephalopathy with Subcortical Cysts 1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 </th <th></th> <th></th> <th></th>			
Krabbe Disease 1 in 15,000 <1 in 1,000,000 LAMA2-related Muscular Dystrophy 1 in 34,000 <1 in 1,000,000 Leigh Syndrome, French-Canadian Type <1 in 50,000 <1 in 1,000,000 Lipoamide Dehydrogenase Deficiency <1 in 50,000 <1 in 1,000,000 Lipoid Congenital Adrenal Hyperplasia <1 in 50,000 <1 in 1,000,000 Lysosomal Acid Lipase Deficiency 1 in 18,000 <1 in 1,000,000 Maple Syrup Urine Disease Type 1B 1 in 25,000 <1 in 1,000,000 Maple Syrup Urine Disease Type la 1 in 42,000 <1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 50,000 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type 1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders	•		
LAMA2-related Muscular Dystrophy 1 in 34,000 <1 in 1,000,000 Leigh Syndrome, French-Canadian Type <1 in 50,000 <1 in 1,000,000 Lipoamide Dehydrogenase Deficiency <1 in 50,000 <1 in 1,000,000 Lipoid Congenital Adrenal Hyperplasia <1 in 18,000 <1 in 1,000,000 Lysosomal Acid Lipase Deficiency 1 in 18,000 <1 in 1,000,000 Maple Syrup Urine Disease Type 1B 1 in 25,000 <1 in 1,000,000 Maple Syrup Urine Disease Type Ia 1 in 13,000 <1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 5,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 16,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosi		· · · · · · · · · · · · · · · · · · ·	
Leigh Syndrome, French-Canadian Type < 1 in 50,000 < 1 in 1,000,000 Lipoamide Dehydrogenase Deficiency < 1 in 50,000 < 1 in 1,000,000 Lipoid Congenital Adrenal Hyperplasia < 1 in 50,000 < 1 in 1,000,000 Lysosomal Acid Lipase Deficiency 1 in 18,000 < 1 in 1,000,000 Maple Syrup Urine Disease Type 1B 1 in 25,000 < 1 in 1,000,000 Maple Syrup Urine Disease Type Ia 1 in 13,000 < 1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 < 1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts < 1 in 50,000 < 1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 < 1 in 1,000,000 Methylmalonic Acidemia, cblA Type 1 in 48,000 < 1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 < 1 in 1,000,000 MKS1-related Disorders < 1 in 50,000 < 1 in 1,000,000 Mucolipidosis IV < 1 in 50,000 < 1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 < 1 in 1,000,000			
Lipoamide Dehydrogenase Deficiency < 1 in 50,000 < 1 in 1,000,000 Lipoid Congenital Adrenal Hyperplasia < 1 in 50,000 < 1 in 1,000,000 Lysosomal Acid Lipase Deficiency 1 in 18,000 < 1 in 1,000,000 Maple Syrup Urine Disease Type 1B 1 in 25,000 < 1 in 1,000,000 Maple Syrup Urine Disease Type Ia 1 in 42,000 < 1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 < 1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 < 1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts < 1 in 50,000 < 1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 < 1 in 1,000,000 Methylmalonic Acidemia, cblA Type < 1 in 50,000 < 1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 < 1 in 1,000,000 MKS1-related Disorders < 1 in 50,000 < 1 in 1,000,000 MKS1-related Disorders < 1 in 50,000 < 1 in 1,000,000 Mucolipidosis IV < 1 in 50,000 < 1 in 1,000,000 Mucolipidosis Type I 1 in 1,000,000 < 1 in 1,000,000			
Lipoid Congenital Adrenal Hyperplasia <1 in 50,000 <1 in 1,000,000 Lysosomal Acid Lipase Deficiency 1 in 18,000 <1 in 1,000,000 Maple Syrup Urine Disease Type 1B 1 in 25,000 <1 in 1,000,000 Maple Syrup Urine Disease Type Ia 1 in 42,000 <1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000		·	
Lysosomal Acid Lipase Deficiency 1 in 18,000 <1 in 1,000,000 Maple Syrup Urine Disease Type 1B 1 in 25,000 <1 in 1,000,000 Maple Syrup Urine Disease Type Ia 1 in 42,000 <1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cbIA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cbIB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cbIC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000			
Maple Syrup Urine Disease Type 1B 1 in 25,000 <1 in 1,000,000 Maple Syrup Urine Disease Type Ia 1 in 42,000 <1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000	, , ,		
Maple Syrup Urine Disease Type Ia 1 in 42,000 <1 in 1,000,000 Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000			
Maple Syrup Urine Disease Type II 1 in 13,000 <1 in 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000			
Medium Chain Acyl-CoA Dehydrogenase Deficiency 1 in 5,900 <1 in 1,000,000 Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000			
Megalencephalic Leukoencephalopathy with Subcortical Cysts <1 in 50,000 <1 in 1,000,000 Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000		•	
Metachromatic Leukodystrophy 1 in 20,000 <1 in 1,000,000 Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000			
Methylmalonic Acidemia, cblA Type <1 in 50,000 <1 in 1,000,000 Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000			
Methylmalonic Acidemia, cblB Type 1 in 48,000 <1 in 1,000,000 Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000			
Methylmalonic Aciduria and Homocystinuria, cblC Type 1 in 16,000 <1 in 1,000,000 MKS1-related Disorders <1 in 50,000 <1 in 1,000,000 Mucolipidosis III Gamma <1 in 50,000 <1 in 1,000,000 Mucolipidosis IV <1 in 50,000 <1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 <1 in 1,000,000	· · · · · · · · · · · · · · · · · · ·		
Mucolipidosis III Gamma < 1 in 50,000 < 1 in 1,000,000 Mucolipidosis IV < 1 in 50,000 < 1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 < 1 in 1,000,000			
Mucolipidosis IV < 1 in 50,000 < 1 in 1,000,000 Mucopolysaccharidosis Type I 1 in 16,000 < 1 in 1,000,000	MKS1-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Mucopolysaccharidosis Type I 1 in 16,000 < 1 in 1,000,000	Mucolipidosis III Gamma	< 1 in 50,000	< 1 in 1,000,000
	•	< 1 in 50,000	< 1 in 1,000,000
Mucopolysaccharidosis Type II1 in 600,0001 in 150,000			
	Mucopolysaccharidosis Type II	1 in 600,000	1 in 150,000



MALE

DONOR 12374

DOB

Ethnicity: Northern European Barcode: 11004212502545

FEMALE N/A

Disease	DONOR 12374 Residual Risk	Reproductive Risk
Aucopolysaccharidosis Type IIIA	1 in 12,000	< 1 in 1,000,000
Aucopolysaccharidosis Type IIIB	1 in 25,000	< 1 in 1,000,000
lucopolysaccharidosis Type IIIC	1 in 37,000	< 1 in 1,000,000
luscle-eye-brain Disease	< 1 in 12,000	< 1 in 1,000,000
IUT-related Methylmalonic Acidemia	1 in 26,000	< 1 in 1,000,000
YO7A-related Disorders	1 in 15,000	< 1 in 1,000,000
EB-related Nemaline Myopathy	< 1 in 6,700	< 1 in 1,000,000
ephrotic Syndrome, NPHS2-related	1 in 35,000	< 1 in 1,000,000
iemann-Pick Disease Type C	1 in 19,000	< 1 in 1,000,000
iemann-Pick Disease Type C2	< 1 in 50,000	
· · · · · · · · · · · · · · · · · · ·		< 1 in 1,000,000
iemann-Pick Disease, SMPD1-associated	1 in 25,000	< 1 in 1,000,000
ijmegen Breakage Syndrome	1 in 16,000	< 1 in 1,000,000
orthern Epilepsy	< 1 in 50,000	< 1 in 1,000,000
rnithine Transcarbamylase Deficiency	< 1 in 1,000,000	1 in 140,000
CCA-related Propionic Acidemia	1 in 4,200	< 1 in 1,000,000
CCB-related Propionic Acidemia	1 in 22,000	< 1 in 1,000,000
CDH15-related Disorders	1 in 5,300	< 1 in 1,000,000
endred Syndrome	1 in 7,000	< 1 in 1,000,000
eroxisome Biogenesis Disorder Type 3	1 in 44,000	< 1 in 1,000,000
eroxisome Biogenesis Disorder Type 4	1 in 9,300	< 1 in 1,000,000
eroxisome Biogenesis Disorder Type 5	< 1 in 71,000	< 1 in 1,000,000
eroxisome Biogenesis Disorder Type 6	< 1 in 50,000	< 1 in 1,000,000
EX1-related Zellweger Syndrome Spectrum	1 in 11,000	< 1 in 1,000,000
nenylalanine Hydroxylase Deficiency		
• • • • • • • • • • • • • • • • • • • •	1 in 5,000	1 in 990,000
KHD1-related Autosomal Recessive Polycystic Kidney Disease	1 in 6,100	< 1 in 1,000,000
lyglandular Autoimmune Syndrome Type 1	1 in 14,000	< 1 in 1,000,000
mpe Disease	1 in 6,300	< 1 in 1,000,000
T1-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
imary Carnitine Deficiency	1 in 11,000	< 1 in 1,000,000
imary Hyperoxaluria Type 1	1 in 35,000	< 1 in 1,000,000
imary Hyperoxaluria Type 2	< 1 in 50,000	< 1 in 1,000,000
rimary Hyperoxaluria Type 3	1 in 13,000	< 1 in 1,000,000
ROP1-related Combined Pituitary Hormone Deficiency	1 in 11,000	< 1 in 1,000,000
vcnodysostosis	< 1 in 50,000	< 1 in 1,000,000
ruvate Carboxylase Deficiency	1 in 25,000	< 1 in 1,000,000
nizomelic Chondrodysplasia Punctata Type 1	1 in 16,000	< 1 in 1,000,000
FEL1-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Illa Disease	< 1 in 30,000	< 1 in 1,000,000
andhoff Disease	1 in 32,000	< 1 in 1,000,000
gawa Syndrome	< 1 in 50,000	< 1 in 1,000,000
nort Chain Acyl-CoA Dehydrogenase Deficiency	1 in 16,000	< 1 in 1,000,000
ogren-Larsson Syndrome	1 in 9,100	< 1 in 1,000,000
nith-Lemli-Opitz Syndrome	1 in 4,900	1 in 970,000
astic Paraplegia Type 15	< 1 in 50,000	< 1 in 1,000,000
	Negative for g.27134T>G SNP	
oinal Muscular Atrophy	SMN1: 2 copies	1 in 110,000
	1 in 770	
ondylothoracic Dysostosis	< 1 in 50,000	< 1 in 1,000,000
Ifate Transporter-related Osteochondrodysplasia	1 in 11,000	< 1 in 1,000,000
M1-related Autosomal Recessive Congenital Ichthyosis	1 in 22,000	< 1 in 1,000,000
P1-related Neuronal Ceroid Lipofuscinosis	1 in 30,000	< 1 in 1,000,000
rosinemia Type I	1 in 17,000	< 1 in 1,000,000
rosinemia Type II	1 in 25,000	< 1 in 1,000,000
H1C-related Disorders		
	1 in 35,000	< 1 in 1,000,000
H2A-related Disorders	1 in 2,200	< 1 in 1,000,000
sher Syndrome Type 3	< 1 in 50,000	< 1 in 1,000,000
ery Long Chain Acyl-CoA Dehydrogenase Deficiency	1 in 8,800	< 1 in 1,000,000
ilson Disease	1 in 8,600	< 1 in 1,000,000
linked Adrenoleukodystrophy	1 in 90,000	1 in 42,000
linked Alport Syndrome	Not calculated	Not calculated
linked Alport Syndrome linked Congenital Adrenal Hypoplasia	Not calculated < 1 in 1,000,000	Not calculated < 1 in 1,000,000



MALE

DONOR 12374

DOB: Ethnicity: Northern European Barcode: 11004212502545

FEMALE N/A

Disease	DONOR 12374 Residual Risk	Reproductive Risk
X-linked Myotubular Myopathy	Not calculated	Not calculated
X-linked Severe Combined Immunodeficiency	< 1 in 1,000,000	1 in 200,000
Xeroderma Pigmentosum Group A	< 1 in 50,000	< 1 in 1,000,000
Xeroderma Pigmentosum Group C	1 in 7,300	< 1 in 1,000,000